Salarius Pharmaceuticals renames to Decoy Therapeutics; ticker changes to DCOY effective Jan 8, 2026

Decoy Therapeutics Inc.

Name change to Decoy Therapeutics Inc. and ticker symbol change from SLRX to DCOY effective January 8, 2026.
No change to shares outstanding, shareholder rights, CUSIP number, or transfer agent.
Focus on AI-enabled peptide-conjugate platform; lead antiviral program attracts BARDA interest.
2026 priorities: advance lead into clinic, expand pipeline, pursue partnerships, and strengthen capital structure.
Company to launch new website decoytx.com for investor relations.

item 5.03 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001615219-26-000013
form_type: 8-K
ticker: DCOY
cik: 0001615219
company_name: Decoy Therapeutics Inc.
filed_at: 2026-01-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.647538+00:00
generated_at: 2026-05-16T11:12:49.384943+00:00
sec_items: ["5.03", "7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001615219-26-000013
json_url: https://secwatch.observer/filing/0001615219-26-000013.json
markdown_url: https://secwatch.observer/filing/0001615219-26-000013.md
text_url: https://secwatch.observer/filing/0001615219-26-000013.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/0001615219-26-000013-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/flks-20260108.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001615219-26-000013

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.